[Serum levels of soluble receptors for tumor necrosis factor in sarcoidosis]. 1995

H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
Second Department of Internal Medicine, Nagoya City University, Japan.

Tumor necrosis factor alpha (TNF-alpha) has been shown to play an important role in granulomatous diseases, including sarcoidosis. TNF-alpha starts affecting cell function by binding to specific, high-affinity receptors on the cell surface, and two types of TNF-alpha receptors have been identified. Recently, soluble forms derived these cell surface receptors (sTNF-R type I and type II) have been shown to exist and have been investigated in several diseases. The levels of sTNF-R type I and type II in serum from patients with sarcoidosis were measured, and the clinical significance of sTNF-R was evaluated. The levels of both sTNF-R type I and type II were significantly higher in serum from patients with sarcoidosis (n = 36) than in serum from control subjects (n = 15): type I, 1.93 +/- 1.28 ng/ml vs 1.31 +/- 0.40 ng/ml, p < 0.01; type II, 3.48 +/- 2.60 ng/ml vs 1.56 +/- 0.35 ng/ml, p < 0.001. The levels of these receptors were significantly higher in patients with active sarcoidosis than in those with inactive sarcoidosis: type I, 2.43 +/- 1.83 ng/ml vs 1.57 +/- 0.45 ng/ml, p < 0.05; type 4.71 +/- 2.24 ng/ml vs 2.25 +/- 0.77 ng/ml, p < 0.01. The levels of sTNF-R type I and type II correlated significantly with the level of ACE, r = 0.70, p < 0.01; and r = 0.55, p < 0.05, respectively. We conclude that measurement of the levels of both types of sTNF-R may be useful in the evaluation of disease activity in sarcoidosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012507 Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands. Besnier-Boeck Disease,Boeck's Sarcoid,Besnier-Boeck-Schaumann Syndrome,Boeck Disease,Boeck's Disease,Schaumann Disease,Schaumann Syndrome,Schaumann's Syndrome,Besnier Boeck Disease,Besnier Boeck Schaumann Syndrome,Boeck Sarcoid,Boecks Disease,Boecks Sarcoid,Disease, Schaumann,Sarcoid, Boeck's,Sarcoidoses,Schaumann's Syndromes,Syndrome, Besnier-Boeck-Schaumann,Syndrome, Schaumann,Syndrome, Schaumann's
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
October 1991, Cancer research,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
January 1996, Anticancer research,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
October 1998, Inflammation,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
September 2006, Archives of internal medicine,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
January 1998, Hepato-gastroenterology,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
September 1993, Leukemia,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
March 1995, The Journal of rheumatology,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
September 1996, Oncology reports,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
January 1997, Lung,
H Kawaguchi, and Y Ina, and S Sato, and S Ito, and Y Sugiura, and Y Hasegawa, and K Takada, and M Yamamoto, and M Morishita
January 2005, Chest,
Copied contents to your clipboard!